Skip to main content

Zymeworks Inc.

ZYMENYSETrackedHealth CareBiotechnology

Market Quote Unavailable · Potential Inactive / Delisted Ticker

Public exchange feeds are not currently returning active trading data for Zymeworks Inc. (ZYME). This company may be delisted, bankrupt, acquired, or halted. To preserve data integrity, prices are never displayed as $0.00. Sourced ESG ratings and sustainability disclosures remain cataloged below.

Coverage
Coverage universe Identity published; no third-party ESG observation yet.
ESG profile reviewed
Last editorial update to this profile.
Quote
Market data unavailableObservation time is shown beside the price.
Methodology
How we rateProvider ratings are shown separately, never blended.

Market overview

Market data unavailable

Massive Stock Widgets has not returned a current, verifiable snapshot for Zymeworks Inc. (nyse:ZYME). Check again later.

Company Profile & Business Model Overview

Zymeworks Inc. (NASDAQ: ZYME) is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, including bispecific antibodies and antibody-drug conjugates, and managing a portfolio of licensed healthcare assets. The company advances oncology and other therapeutic candidates while partnering and licensing certain assets to third parties. Headquartered in Vancouver, British Columbia, Zymeworks operates globally with clinical programs and licensed products contributing to its scale.

Sustainability Strengths & Catalysts (Pros)

  • Robust biologics platform: Zymeworks has engineered multifunctional antibody platforms (e.g., Azymetric and EFECT) enabling development of differentiated therapeutics, which can improve targeting precision and potentially reduce off-target effects relativ
  • Partnerships and licensing diversify risk: The company manages licensed healthcare assets and has entered collaborations that distribute development and commercialization risk, which can enhance financial resilience and continuity of patient access to the
  • Clinical-stage innovation focus: Active clinical pipelines in oncology and other indications demonstrate ongoing R&D investment in treatments for serious diseases, aligning corporate activity with significant public health needs.

Material Risks & Governance Concerns (Cons)

  • Clinical and development risk: As a clinical-stage biopharma, Zymeworks faces high technical and regulatory failure risk for its candidates, which can lead to stranded assets, layoffs, or supply disruptions affecting stakeholders.
  • Limited commercial revenue diversification: Reliance on licensing deals and future commercialization of a small number of assets concentrates financial and operational risk, potentially affecting long-term sustainability and investor returns if key progra

Related ESG Peer Equities

Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.

Explore Health Care Peers →

ESG & Sustainability Rating Breakdown

MSCI and Sustainalytics ratings shown side by side, never blended into a single score.

Third-party ratings

Coverage PendingThird-Party ESG Coverage Under Review

Formal published scorecards from MSCI ESG Research and Sustainalytics are not currently available for this ticker. The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.

Data integrity and methodology

MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.

FAQ

Frequently Asked Questions

Direct answers on sustainability scores, risk methodologies, and peer rankings.

What is Zymeworks Inc. (ZYME)'s ESG rating and sustainability score?

Formal published scorecards from MSCI and Sustainalytics are under ongoing review for Zymeworks Inc. (ZYME). The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.

Is Zymeworks Inc. considered an ESG leader or laggard in Health Care?

Independent benchmark status for Zymeworks Inc. is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.

What are the main ESG risks and controversies for Zymeworks Inc.?

Key material risks for Zymeworks Inc. include: Clinical and development risk: As a clinical-stage biopharma, Zymeworks faces high technical and regulatory failure risk for its candidates, which can lead to stranded assets, layoffs, or supply disruptions affecting stakeholders.; Limited commercial revenue diversification: Reliance on licensing deals and future commercialization of a small number of assets concentrates financial and operational risk, potentially affecting long-term sustainability and investor returns if key progra. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.

How does The Impact Investor evaluate ESG stock profiles?

The Impact Investor presents third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.